NEWS ALERT
Biocurex, Inc. (OTCBB: BOCX)
6 Month Target Price: $1.26
Shares Outstanding 15 million
Approx. Float 12 million
6 Month Price Proj. $1.26
A Few Reasons to Own BOCX:
BOCX has patented and proprietary technology that is leading the way in early cancer detection.
BOCX is currently developing and commercializing cancer diagnostic products based upon their breakthrough RECAFTM cancer marker technology.
A vaccine based on BOCX's proprietary RECAFTM technology that would protect against most types of cancer has a $2B market potential in U.S. alone.
Radioisotope imaging of RECAFTM positive cancer cells can be obtained with standard hospital equipment. Projected as a $1B U.S. market share for BOCX.
$ 2 Billion Dollar market targeted for BOCX's single serum test for the diagnosis of numerous types of cancer. To be launched under the name Serum-RECAFTM.
$3 Billion Dollar market share is seen as realistic as BOCX joins the Antibody Therapy arena with very favorable results from preliminary studies based on BOCX's RECAFTM technology.
BOCX targets growing market for minimizing or eliminating side effects of cancer chemotherapy, utilizing its RECAFTM antibodies for drug and radioisotope delivery.
BOCX is seen as a prime-licensing candidate based on the multitude of clinical uses of BOCX's proprietary RECAF TMtechnology.
BOCX has assembled a team of renowned individual scientists and experts under the direction of Dr. Phillip Gold, the most eminent investigator in the cancer marker field.
Investigators at BOCX have demonstrated that leukemia can be diagnosed and monitored utilizing BOCX's RECAFTM staining technology. By cleansing patients' bone marrow of cancer cells, need for bone marrow transplants might be eliminated.
BOCX's Histo-RECAFTM, a special cancer detection kit for tissues, has been cleared for sale by the FDA for U.S. markets, with an early projected market potential of $200 million.
Histo-RECAFTM HAS BEEN CLEARED BY THE FDA FOR SALE IN THE USA.
UPDATE
Unbelievable! Great New! PR like this could put BOCX into the Major Leagues. Sometimes less said is better. The PR speaks for itself (read below).
What more can a little R&D Biotech Company like BOCX announce than this, in our opinion, it doesn't get much better, but you never know.
With an FDA approval and a US patent and a market potential of $2 Billion Dollars, it appears to us that BOCX is now on their way to generating Revenues and Profits.
This PR should peek the interest of the short sellers, in our opinion, at least in the short term to get them to cover by buying back their stock.
We guess the next PR pertaining to this PR will probably be Licensing and Marketing Agreements, but who knows?
We believe the next several trading days should be pretty interesting based on this new PR.
Keep a real close eye on BOCX, and Watch This Stock Trade.
Press Release - Source: BioCurex, Inc.
March 10, 2003
BioCurex Granted U.S. Patent For Cancer Diagnostic Products and FDA Clearance with a Market Potential worth $2 Billion Dollars
RANCHO SANTA MARGARITA, California, -- BioCurex Inc. (OTC BB:BOCX) announces that the U.S. Patent office has granted patent Nr. US6,514,685 B1 entitled "DETECTION OF CANCER USING ANTIBODIES TO THE AFP-RECEPTOR" [RECAFTM].
RECAFTM is a novel tumor marker, which is a molecule that is expressed in cancer cells but not on normal or benign tumor cells. RECAFTM has been found in all cancers so far studied, including breast, lung, stomach, colorectal, ovarian and prostate cancers. The RECAFTM molecule has been found in one hundred percent (100%) of breast cancers.
The U.S. patent covers 17 claims, which include the technologies used in the Company's Histo-RECAFTM and Cryo-RECAFTM kits as well as in the Serum-RECAFTM kits to be released for cancer diagnosis on blood samples. The patent also covers other in-vitro applications for diagnosis, screening and follow-up of cancer and leukemia. In-vivo RECAFTM applications, such as cancer imaging, therapy and vaccination remain pending under a continuation in part of the original application.
The patent covers BioCurex's Histo-RECAFTM kit, which has been now been cleared for sales by the FDA.
BioCurex has already been issued patents in Australia and Russia and has patent pending's in Canada and Japan and most European countries with pending approvals for diagnostic and therapeutic applications which have a much greater market share potential than already stated.
Dr. Ricardo Moro stated: "As the inventor of this patent, I am elated by the decision of the U.S. Patent Office to grant this approval. The patent office is extremely thorough in their scrutiny and their approval provides a great deal of credibility to our technology. As the President of the Company, I am even more excited because now we have a final patent that we can license to the dominating biotechnology/pharma companies in the field of cancer diagnosis and screening. The market size for cancer diagnostics alone is estimated to be over $2 billion dollars not to mention the market potential for therapeutic applications."
Dr. Gerald Wittenberg, Chairman of the Board added: "We are very pleased with the granting of this patent. We have committed a great deal of effort and resources to developing new cancer diagnostic products. The granting of our patent by the U.S. Patent Office and the clearance of our first product by the United States Food and Drug Administration (FDA) clearly indicates that we are on the right track. We are delivering on what we planned to achieve and we will continue to advance our technologies for the benefit of cancer patients."
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAFTM, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAFTM kits provide proof of concept for the RECAF technology. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited distribution of this material by e-mail or facsimile by unauthorized parties.
Valuation
In our opinion, nothing can be more exiting than a Biotech Company. Biotech Company's by definition are R&D Company's trying to find cures for various human diseases.
Biotech Company's start off in stages, first identifying a disease, the market for it and developing the cure. These companies once they have gained an FDA approval for their product generally team with a large Pharmaceutical Company for either licensing rights or distribution. Whenever these small Biotech Company's gain an FDA approval for their product, the stock, if publicly traded generally ROCKETS in price.
In the case of BOCX, what we have here is company that has just about been left for dead by Wall Street, in our opinion, Under Followed and Overlooked.
BOCX has already gained an FDA approval for Histo-RECAFTM , with a projected market potential of $ 200 Million Dollars.
In fact, according to BOCX, they anticipate manufacturing for their products to begin within 90 days, and starting to generate Revenues and Profits within 180 days. Once revenues begin, BOCX is projecting first year or next years revenues to approximate $ 19 Million Dollars with 75% PROFIT MARGINS. The following year BOCX anticipates Revenues of $ 51 Million Dollars with 75% PROFIT MARGINS.
According to Multex, for those Biotech Company's that generate revenues and earnings on a price to sales ratio and price earnings ratio, Biotech's trade in the market at 8.81 times sales and 29.4 times earnings.
If over the next 6 months BOCX can demonstrate to Wall Street that they are for real, and can show through licensing and marketing agreements that $ 19 Million Dollars in revenues next year is realistic, then if BOCX were to trade in the market place at JUST 1 TIMES NEXT YEARS ANTICIPATED REVENUES (which represents a 90% DISCOUNT to its peers) based on the number of shares outstanding this would equate to STOCK PRICE OF $1.26 PER SHARE.
One never knows, BOCX could be one of Wall Streets best kept secrets, but maybe the cat is now coming out of the bag and the timing of this new Investor Awareness Campaign could be good timing in regards to new PR forthcoming to maybe Rocket the stock or maybe it is just another Investor Awareness Campaign.
One never knows, but keep a watchful eye on BOCX near term and as always Watch This Stock Trade.
Conclusion
On another note, there have been recent published reports that BOCX has been the victim of Short Selling. Investors generally short stocks for several reasons first among them is their belief that a stock is overvalued and ripe for a decline, and secondly the fundamentals make no sense and believe a stock should be worthless.
BOCX is currently trading at a new low, although our profiles can be construed as biased since we get paid to disseminate our clients information to the investing public. We never know why we get hired we just get hired. In our opinion, from past experience maybe BOCX has some positive developments occurring near term that BOCX wants to convey to the investing public, but either way with the history of Biotech Stocks in general, and published reports on Short Selling, in our opinion, this just might be a Short Squeeze In Motion.
******* Important Notice and Disclaimer: Please Read *******
Investor Insights, and affiliates (II), publishes reports providing information on selected companies that II believes has investment potential. II is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. II accepts no liability for any loss arising from an investor's reliance on or use of this report. An investment in BOCX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. An affiliate of II has been compensated three hundred twelve thousand five hundred free trading shares of common stock of BOCX and three hundred thousands options exercisable into BOCX at .20 cents per share by a third party for the publication and circulation of this report. II intends to sell all or a portion of the of the BOCX stock at or about the time of publication of this report. II intends to sell all or a portion of the of the BOCX stock at or about the time of publication of this report. Subsequently II may buy or sell shares of BOCX stock in the open market. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. For further details concerning these risks and uncertainties, see the SEC filings of BOCX including the company's most recent annual and quarterly reports. |
